P1144 DETERMINING THE COMPARATIVE EFFECTIVENESS OF EMERGING TREATMENT REGIMENS FOR HEPATITIS C VIRUS (HCV) INFECTION FROM SINGLE ARM PHASE III TRIALS
Melanie Quintana(Berry & Associates (United States)), Scott Berry(Queen's University), Michelle A. Detry(Berry & Associates (United States)), Eric S. Daar(UCLA Medical Center), Yuping Yuan, Kristine Broglio(Statistical Research (United States)), T. Kim Le, Anupama Kalsekar(Bristol-Myers Squibb (United States)), Robert Lewis(The Lundquist Institute)
Cited by 2
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
|New England Journal of Medicine|2002|1.1k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951